Unknown

Dataset Information

0

[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].

ABSTRACT: Lung cancer has the highest morbidity and mortality among malignant tumors worldwidely. Targeted therapy related to non-small cell lung cancer (NSCLC) is the research hotspot in recent year. The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has brought a huge change in the treatment of patients with EGFR mutation. The patients with EGFR exon20 insertion are specific cohort in NSCLC. Reviewing the clinical researches to EGFR exon20 insertion mutation positive NSCLC, as well as summarizing character, testing methods and treatment, will provide a help for clinical application, bringing more benefits for patients at the same time.

SUBMITTER: Zhou W 

PROVIDER: S-EPMC7049789 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].

Zhou Wensheng W   Zhang Wei W   Han Baohui B  

Zhongguo fei ai za zhi = Chinese journal of lung cancer 20200201 2

Lung cancer has the highest morbidity and mortality among malignant tumors worldwidely. Targeted therapy related to non-small cell lung cancer (NSCLC) is the research hotspot in recent year. The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has brought a huge change in the treatment of patients with EGFR mutation. The patients with EGFR exon20 insertion are specific cohort in NSCLC. Reviewing the clinical researches to EGFR exon20 insertion mutation positiv  ...[more]

Similar Datasets

Unknown Targeting <i>EGFR</i> exon 20 insertion mutations in non-small cell lung cancer.
| S-EPMC6405763 | biostudies-literature
Unknown EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
| S-EPMC6580637 | biostudies-literature
Unknown Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
| S-EPMC9262839 | biostudies-literature
Unknown Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea.
| S-EPMC6473281 | biostudies-literature
Unknown Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations.
| S-EPMC8147255 | biostudies-literature
Unknown Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma.
| S-EPMC6806250 | biostudies-literature
Unknown Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions.
| S-EPMC8455549 | biostudies-literature
Unknown EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
| S-EPMC3714231 | biostudies-literature
Unknown EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors.
| S-EPMC8183979 | biostudies-literature
Unknown Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer.
| S-EPMC8648093 | biostudies-literature